Side Effects of valsartan: A Synthesis of Findings from 26 Studies

  1. Home
  2. Side Effects of valsartan
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of valsartan: A Synthesis of Findings from 26 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of valsartan: A Synthesis of Findings from 26 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Valsartan is an angiotensin II receptor blocker (ARB) widely used for treating high blood pressure. These studies evaluate the safety and efficacy of valsartan, investigate its interactions with other drugs and report potential side effects. 8 reported that valsartan administered orally to marmosets for two weeks resulted in side effects such as weight loss, anemia, and kidney abnormalities. 24 presents a case report of a patient taking valsartan who experienced side effects including oral mucosal lesions. 18 demonstrates the effectiveness of a combination drug (LCZ696) containing valsartan and sacubitril in treating heart failure. 11 reports that sacubitril/valsartan is a new drug effective in treating heart failure. 4 indicates the effectiveness of sacubitril/valsartan in treating heart failure, and its efficacy is confirmed in real-world clinical practice. 3 reports that sacubitril/valsartan is effective in treating heart failure, especially in patients with reduced systolic function. 10 reports the effectiveness and safety of sacubitril/valsartan in treating heart failure. 19 suggests that the dosage of sacubitril/valsartan needs to be adjusted depending on the individual patient. 1 reports on the effects of topical valsartan administration on diabetic ulcers. 12 examines the safety and efficacy of sacubitril/valsartan in children. 14 compares the blood pressure-lowering effects of valsartan and azilsartan. 16 reports on contaminants found during the manufacturing process of valsartan and other sartan-based drugs. 9 explains drug interactions involving valsartan. 25 compares the blood pressure-lowering effects of valsartan and olmesartan. 26 shows that valsartan is effective in patients whose blood pressure is not controlled by olmesartan. 21 reports that valsartan is effective in treating heart failure and can also reduce the need for diuretics. 17 reports on the development of oral disintegrating tablets containing valsartan. 7 reports on side effects of valsartan and other medications in elderly patients with heart failure. 23 examines the initiation of valsartan treatment in outpatient settings. 2 reports on drug interactions between valsartan and cilnidipine. 5 reports on the combined therapy of valsartan and hydrochlorothiazide. 20 reports that sacubitril/valsartan is effective in treating heart failure. 22 compares the blood pressure-lowering effects of valsartan and azilsartan. 13 analyzes adverse drug reaction reports in Ukraine involving valsartan and other medications. 15 reports on the treatment of heart failure in elderly patients. 6 examines the impact of valsartan on lysozyme aggregation.

Reasons for Side Effects

Side effects of valsartan can be caused by the mechanism of action of the drug and the body's response. For instance, valsartan lowers blood pressure by inhibiting the angiotensin II receptor, which can lead to vasodilation and increased blood flow to the kidneys, potentially resulting in side effects such as hypotension and renal dysfunction. 8 18 9 20 13

Common Side Effects

Hypotension

One of the most common side effects of valsartan is hypotension. Because valsartan dilates blood vessels, it can lead to a decrease in blood pressure. 18 19 23 20

Renal Dysfunction

Valsartan can cause renal dysfunction by increasing blood flow to the kidneys. 8 18 20 15

Gastrointestinal Symptoms

Valsartan can cause gastrointestinal side effects. 14 13

Allergic Reactions

Valsartan can cause allergic reactions. 13

Other

Valsartan can also cause side effects such as headache, dizziness, fatigue, and cough. 9 20 13

Countermeasures for Side Effects

Hypotension

If hypotension occurs, valsartan dosage may be reduced or discontinued under the guidance of a physician. 19 23

Renal Dysfunction

If renal dysfunction occurs, valsartan dosage may be reduced or discontinued under the guidance of a physician. 8 18 20 15

Gastrointestinal Symptoms

If gastrointestinal symptoms occur, valsartan dosage may be reduced or discontinued under the guidance of a physician. 14 13

Allergic Reactions

If an allergic reaction occurs, seek immediate medical attention. 13

Other

Consult a doctor if other side effects occur. 9 20 13

Comparison Across Studies

Commonalities Across Studies

These studies aim to assess the safety and efficacy of valsartan. They also provide vital information regarding the side effects of valsartan. 8 24 18 11 4 3 10 19 1 12 14 16 9 25 26 21 17 7 23 2 5 20 22 13 15 6

Differences Across Studies

These studies differ in terms of valsartan administration methods, the targeted patient populations, and evaluation criteria. 8 24 18 11 4 3 10 19 1 12 14 16 9 25 26 21 17 7 23 2 5 20 22 13 15 6

Points to Note for Real-Life Application

While valsartan is an effective drug for treating high blood pressure, it poses the risk of side effects. When taking valsartan, always follow your doctor's instructions carefully, and consult your doctor immediately if you experience any side effects. 8 24 18 11 4 3 10 19 1 12 14 16 9 25 26 21 17 7 23 2 5 20 22 13 15 6

Limitations of Current Research

These studies are designed to evaluate the safety and efficacy of valsartan. However, they may not be applicable to all individuals. Additionally, these studies do not evaluate the long-term effects of valsartan. 8 24 18 11 4 3 10 19 1 12 14 16 9 25 26 21 17 7 23 2 5 20 22 13 15 6

Future Research Directions

Research is needed to evaluate the long-term effects of valsartan and its impact on specific patient populations. Additionally, the development of new treatment methods to minimize the side effects of valsartan is necessary. 8 24 18 11 4 3 10 19 1 12 14 16 9 25 26 21 17 7 23 2 5 20 22 13 15 6

Conclusion

Valsartan is an effective drug for treating high blood pressure, but it carries the risk of side effects. When taking valsartan, strictly follow your doctor's instructions and consult your doctor immediately if you experience any side effects. 8 24 18 11 4 3 10 19 1 12 14 16 9 25 26 21 17 7 23 2 5 20 22 13 15 6

Literature analysis of 26 papers
Positive Content
22
Neutral Content
2
Negative Content
2
Article Type
3
2
2
11
24
1.

Nociceptive and Transcriptomic Responses in a Swine Diabetic Wound Model Treated With a Topical AT1R Antagonist.

Author: WeissMiriam N, MocciEvelina, ZhuShijun, DavenportMatthew J, EnglishEmily, RennCynthia L, DorseySusan G

Pain relief

Treatment-resistant wounds in diabetic patients often cause significant pain. This study explored the potential of targeting the angiotensin 1 receptor (AT1R) with topical treatments to manage pain.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

2.

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers.

Author: LeeJieon, LeeHoward, JangKyungho, LimKyoung Soo, ShinDongseong, YuKyung-Sang

This study investigated the potential drug-drug interaction between cilnidipine and valsartan, two common hypertension medications, in healthy men. The pharmacokinetic, pharmacodynamic, and tolerability profiles of each drug were assessed when given alone and in combination.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Sacubitril/valsartan for heart failure with reduced ejection fraction: A first real-life observational study in Poland.

Author: LelonekMałgorzata, Wiśniowska-ŚmiałekSylwia, RubiśPaweł, NowakowskaIzabela, PawlakAgnieszka

HF symptom improvement
Improved EF
Increased 6MWP
HF hospitalization
Side effects
Treatment discontinuation

This observational multicenter study evaluated the effectiveness, tolerance, and safety of sacubitril/valsartan in 89 Polish patients with stable chronic heart failure with reduced ejection fraction (HFrEF). The study found that sacubitril/valsartan treatment was safe and associated with significant clinical and objective improvement. The non-survivors had more advanced HFrEF, suggesting that initiation and uptitration of sacubitril/valsartan should be done early.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

7.

The Prevalence of Adverse Drug Reactions and Adverse Drug Events from Heart Failure Medications in Frail Older Adults: A Systematic Review.

Author: DuongMai H, GnjidicDanijela, McLachlanAndrew J, SakirisMarissa A, GoyalParag, HilmerSarah N

Adverse drug reactions

This review focuses on the prevalence, causality, and severity of adverse drug reactions (ADRs) or adverse drug events (ADEs) related to heart failure medications in frail older adults, comparing them to non-frail older adults.

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Approaches of validation of a 2-week combined repeated oral dose toxicity study with plasma micro sampling toxicokinetics (PMS-TK) in common marmosets.

Author: MochizukiHidemi, MurotaNaoya, SatoShin-Ichi, NiiKazuo, KouheiYoko, TaniguchiMasahiro, InoueRyo, NishimeChiyoko, TsutsumiHideki

Animal welfare

This study demonstrated that a combined repeated dose toxicity study with toxicokinetics (TK) analysis is feasible in common marmosets using valsartan. This approach helps reduce the number of animals used while still providing valuable safety data.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Validation StudyResearch to assess the validity and reliability of new measurement methods or diagnostic tests.

Language : English

9.

Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450.

Author: YangRuirui, LuoZhiqiang, LiuYang, SunMohan, ZhengLing, ChenYingying, LiYanping, WangHao, ChenLingzhu, WuMing, ZhaoHuihui

ARBs for hypertension
ARB side effects

Angiotensin receptor blockers (ARBs) are effective for treating hypertension, but may cause side effects such as headache, upper respiratory infection, back pain, and fatigue.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

The Efficacy and Safety of Sacubitril-Valsartan for the Treatment of Heart Failure in Adults: A Meta-Analysis.

Author: TianQingshan, XiongZhiping, FanHouDe, NingTing, ZhengZhenZhong

Heart failure treatment
Reduced mortality
Adverse effects

Sacubitril-valsartan (SV) is effective in treating heart failure, reducing hospitalization and cardiovascular mortality. Its adverse effects are comparable or fewer than other heart failure medications.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Neprilysin Inhibitors: Emerging Therapy for Heart Failure.

Author: OwensAnjali Tiku, BrozenaSusan, JessupMariell

Heart failure treatment
Alzheimer's disease
Angioedema

A new drug combining a NEP inhibitor and an angiotensin receptor blocker has shown promise in reducing hospitalization and mortality for patients with systolic heart failure. However, potential side effects like angioedema and Alzheimer's disease, along with cost and patient selection, are challenges for wider implementation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

Does sacubitril/valsartan work in children with heart failure?-a pilot study.

Author: XuYahe, ZhangMingjie, ChenYijun, ChenXi, SongWenting, ZhuLimin, LiuLiping, GongXiaolei, ZhangYuqi, XuZhuoming

This pilot study evaluated the safety and effectiveness of sacubitril/valsartan in children with heart failure (HF). The goal is to understand how this medication works in this population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

14.

Azilsartan: a newly approved angiotensin II receptor blocker.

Author: LamSum

blood pressure lowering
well-tolerated
hypotension
worsening of renal function

Azilsartan is a new angiotensin II receptor blocker approved for the treatment of hypertension. The medication is effective in lowering blood pressure and is generally well tolerated.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

19.

Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice.

Author: DuAmy X, WesterhoutCynthia M, McAlisterFinlay A, ShanksMiriam, OuditGavin Y, PatersonDavid Ian, HanninenMikael, ThomasJissy, EzekowitzJustin A

Improved heart failure management
Drug side effects

Sacubitril/valsartan is a medication for heart failure. This study examined the use and tolerability of this drug in a heart failure clinic. The findings revealed that achieving the target dose was challenging due to various factors, including side effects and patient non-compliance. Improved patient and clinician support may enhance the use of this medication.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

[Angiotensin-receptor- and neprilysin-inhibition: a new option against heart failure].

Author: BruhnClaudia

Cardiovascular death reduction
Heart failure hospitalization reduction
Angioedema
Hyperkalemia
Hypotension
Impaired renal function

Sacubitril/valsartan is a new drug for treating heart failure that has shown benefits over enalapril in reducing death and hospitalization. Potential side effects include hypotension, angioedema, impaired renal function, and elevated potassium levels.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : German

21.

Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?

Author: KerrBrian, PharithiRebabonye B, BarrettMatthew, HalleyCarmel, GallagherJoe, LedwidgeMark, McDonaldKenneth

Improved heart function
Reduced diuretic need
Diuretic side effects

This study discusses the role of diuretics in heart failure (HF) management, noting that while they are beneficial, they can have side effects. Newer therapies, like ARNi, may reduce the need for diuretics in HFrEF, highlighting the importance of individual assessments of diuretic requirements.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

22.

Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.

Author: SicaDomenic, WhiteWilliam B, WeberMichael A, BakrisGeorge L, PerezAlfonso, CaoCharlie, HandleyAlison, KupferStuart

Higher rates of hypertension control
Superior efficacy to VAL
Changes in serum creatinine

Azilsartan medoxomil (AZL-M) demonstrated superior efficacy to valsartan in lowering blood pressure in patients with primary hypertension.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

23.

Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients.

Author: RerickLindsey, ElstonColleen, KesterJordan, MonteparaCourtney, GenglerBrooke

Dose reductions
Hypotension

This study investigated the real-world initiation of sacubitril/valsartan therapy for heart failure. It found that almost half of patients were started outside guideline recommendations, which increased the risk of hypotension and dose reductions. This highlights the need for improved adherence to guidelines when prescribing this medication.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

25.

Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis.

Author: AlmarjanAmjaad Ibrahim, AlmarjanSara Abdulaziz, MasoudAhmed Taher

Antihypertensive effects

Sacubitril/valsartan, a drug with neprilysin inhibition and angiotensin receptor-blocking properties, is expected to have strong antihypertensive effects. However, there is limited evidence to compare its safety and efficacy with olmesartan in patients with hypertension.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

26.

Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.

Author: CheungDeanna G, AizenbergDiego, GorbunovVladimir, HafeezKudsia, ChenChien-Wei, ZhangJack

Blood pressure control

Sacubitril/valsartan was more effective than continued olmesartan in lowering blood pressure in patients with mild to moderate hypertension who were not adequately controlled with olmesartan alone. The drug was generally safe with comparable side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.